Nasdaq Cytk News Today

Fisher Asset Management LLC purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 535,954 shares of the biopharmaceutical company’s stock, valued at approximately $44,747,000. Fisher Asset Management LLC owned approximately 0.55% of Cytokinetics […]

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price objective […]

Sage Rhino Capital LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,439 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. Several other […]

Needham & Company LLC reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $108.00 price objective on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Oppenheimer reiterated an outperform rating and […]

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month […]

HC Advisors LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,243 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. Other institutional investors and hedge […]

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the...

Cytokinetics (NASDAQ:CYTK – Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.35), Briefing.com reports. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $7.62 million. The firm’s quarterly revenue was […]

Moody Aldrich Partners LLC increased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,448 shares of the biopharmaceutical company’s stock after purchasing an additional 5,172 shares during […]

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 13,750,000 shares, a decrease of 8.8% from the December 31st total of 15,080,000 shares. Currently, 14.7% of the company’s stock are short sold. Based […]